Akashi Therapeutics Is A Clinical Stage Biotechnology Company Developing A Portfolio Of Products For Duchenne Muscular Dystrophy And Other Rare Diseases The Lead Clinical Asset Is Ht 100And Drug Candidate With Potent Anti Inflammatory And Anti Fibrotic Properties That Also Promotes Healthy Muscle Regeneration The Company S Second Clinical Candidate Is Dt 200A Selective Androgen Receptor Modulatorsarm Targeted To Build Muscle Mass And Strength Akashi Is A Combination Of Halo Therapeutics And Dart Therapeuticstwo Companies Founded As A Collaboration Between Patient Advocacy Organizations And Biotechnology Industry Veterans Akashi Is Lead By A Team Of Experienced Drug Developers
